Faculty Collaboration Database

In vitro mutagenicity of the plasmacytomagenic agent pristane (2,6,10,14-tetramethylpentadecane). Cancer Lett 1997 Feb 26;113(1-2):71-6

Date

02/26/1997

Pubmed ID

9065804

DOI

10.1016/s0304-3835(97)04597-7

Scopus ID

2-s2.0-0031586754 (requires institutional sign-in at Scopus site)   4 Citations

Abstract

Pristane is known to induce a distinct type of B-cell-derived malignant lymphoma, plasmacytoma, after administration into the peritoneal cavity of genetically susceptible BALB/cAnPt mice. Since the mechanism of pristane-induced plasmacytoma development is poorly understood, we chose to examine the possibility that pristane is mutagenic in rodent cells and decided to use bacteriophage lambda-derived lacI/lacZ genes as target/reporter to quantitate mutagenesis. Here we show that in vitro exposure to micromolar amounts of pristane, delivered as an inclusion complex with beta-cyclodextrin, resulted in 1.7-fold and 6.2-fold increases of mutant frequencies over controls in a cell line of rat fibroblasts and primary mouse B lymphocytes, respectively. We conclude that pristane can be mutagenic to mammalian cells, yet are currently unable to explain the mechanism of mutagenicity. It is suggested that B-cell mutagenesis contributes to the plasmacytomagenic activity of pristane in vivo.

Author List

Felix K, Potter M, Bornkamm GW, Janz S

Author

Siegfried Janz MD Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Amino Acid Sequence
Animals
B-Lymphocytes
Base Sequence
Carcinogens
Cells, Cultured
Fibroblasts
Mice
Mutagenicity Tests
Mutagens
Rats
Terpenes